The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus

1. Episode · Sep 30, 2026

   Daily Roundup | uniQure's Mixed Huntington's Readout & AstraZeneca's $2B Summit Deal (opens the original)

   Episode notes · Neutral tone

   Read excerpt

   September 29 edition: uniQure's four-year Huntington's readout is mixed, while its filing rests on earlier data. AstraZeneca agrees to invest $2 billion in Summit alongside a cancer-combination program, without acquiring Summit's drug rights. In the roundup: Veracyte's retrospective Decipher analysis in prostate cancer; FDA approval of Teva's Xgeva biosimilar; and Novo's license to Hengrui's early oral GLP-1/GIP program. Invivyd reports tolerability, not protection, results for VYD2311, and we e

   Feedback

2. Episode · Sep 29, 2026

   Daily Roundup| Mirum's Brelovitug Wins Phase 3 on Two Schedules & Kodiak's Zenkuda: 54% Reach Six-Month Dosing (opens the original)

   Episode notes

   Read excerpt

   Mirum's brelovitug met Phase 3 AZURE-1's virus-plus-ALT endpoint on weekly and every-four-week dosing in chronic hepatitis delta; durable liver outcomes were not shown. Kodiak's Zenkuda and tabirafusp were noninferior to aflibercept 2 mg on vision in wet AMD, and 54% of Zenkuda patients reached a 24-week interval; neither was compared with newer alternatives. 4DMT started Phase 3 testing of 4D-150 in diabetic macular edema, while Roche will return emugrobart rights to Chugai after an obesity tri

   Feedback

3. Episode · Sep 28, 2026

   Full Week in Review | Gilead's Anito-cel, Genentech's Gazyva & Myeloma's New Cure Standard (opens the original)

   Episode notes

   Read excerpt

   This full Week in Review is a comprehensive review of the week's covered stories across oncology, kidney and immune disease, respiratory disease, metabolic disease, neuroscience, rare disease and ophthalmology, plus financings, deals and five events ahead. Gilead's anito-cel gets its full peer-reviewed Phase 1 record before a December FDA target; myeloma groups define cure; and Genentech's Gazyva wins approval to reduce relapse risk in childhood-onset nephrotic syndrome. Also in the review: Lill

   Feedback

4. Episode · Sep 26, 2026

   Daily Roundup | Mirum Wins FOP Approval Despite Primary Endpoint Miss & Carvykti's Five-Year Data (opens the original)

   Episode notes

   Read excerpt

   Mirum's Atebrioz (zilurgisertib) wins FDA approval for FOP despite a primary-endpoint miss; Carvykti (ciltacabtagene autoleucel) shows five-year disease control without maintenance in half of 20 myeloma patients. aTyr plans another efzofitimod trial in sarcoidosis. The roundup covers Pharming's Joenja (leniolisib), ADARx's IPO, Canada's Epkinly (epcoritamab) expansion, Novo–Nanexa's long-acting peptide deal, FDA nominee Heidi Overton's hearing, and Medicaid's GENEROUS pricing plan. September 25

   Feedback

5. Episode · Sep 25, 2026

   Daily Roundup| Merck–Eisai Win Kidney Cancer Approval & Lilly Joins Weekly Insulin Race (opens the original)

   Episode notes

   Read excerpt

   Welireg plus Lenvima gains FDA approval in advanced clear-cell kidney cancer, with better disease control but no demonstrated survival advantage. Lilly says FDA approved weekly insulin Onswik, entering a market where Novo’s Awiqli is already available. Merck’s remigromig meets its pivotal vision goal, but safety and dosing questions remain. Plus: Acadia advances after a Phase 2 miss; Kyverna reports autoimmune follow-up; Elevar gains bile-duct cancer approval; Takeda’s Adzynma gets a boxed warni

   Feedback

Last 90 days. Choose a month to open its work.

Named in the text we hold. One piece can cover several.

Not enough subject data for this period yet.

No verified audience measurement yet.